Tiotropium Induced Bronchodilation in Lung CT Scored Emphysema
Information source: Gelb, Arthur F., M.D.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: COPD; Emphysema
Intervention: tiotropium (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Gelb, Arthur F., M.D. Official(s) and/or principal investigator(s): Arthur F Gelb, MD, Principal Investigator, Affiliation: Arthur F Gelb Medical Corporation
Summary
To evaluate if tiotropium (Spiriva)induced bronchodilation of inspiratory capacity in
patients with moderate to severe copd subjected to metronome paced hyperventilation induced
dynamic hyperinflation is dependent upon the extent of underlying emphysema as determined by
high resolution-thin section CT lung.
Clinical Details
Official title: Effectiveness of Tiotropium to Maintain Inspiratory Capacity Against Metronome Paced Hyperventilation Induced Dynamic Hyperinflation in COPD Patients With Lung CT Scored Emphysema
Study design: Observational Model: Case-Crossover, Time Perspective: Retrospective
Primary outcome: Correlate tiotropium induced increase in inspiratory capacity (IC)and FEV 1 with extent of emphysema as scored by lung CT.
Secondary outcome: Correlate decrease in IC and FEV 1 following dynamic hyperinflation with underlying emphysema.
Detailed description:
We will analyze post hoc, data that was previously published: Gelb AF et al. Chest
2006;131: 690-695. We have shown that tiotropium increases resting inspiratory capacity
thereby providing lung volume protection against metronome paced hyperventilation induced
dynamic hyperinflation. End point will be to correlate increase in tiotropium induced FEV
1(L) and inspiratory capacity with extent of underlying emphysema as scored by lung CT (
Gelb AF et al: Chest 1996; 109: 353-359)in 29 patients with COPD. We will also correlate the
decrease in inspiratory capacity following metronome paced hyperventilation induced dynamic
hyperinflation with extent of lung CT scored emphysema.
Eligibility
Minimum age: 40 Years.
Maximum age: 85 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria
- moderate to severe copd
Exclusion Criteria
- unable to tolerate tiotropium
- unable to perform metronome paced hyperventilation induced dynamic hyperinflation
Locations and Contacts
Arthur F Gelb Medical Corporation, Lakewood, California 90712, United States
Additional Information
Related publications: Gelb AF, Taylor CF, McClean PA, Shinar CM, Rodrigues MT, Gutierrez CA, Chapman KR, Zamel N. Tiotropium and simplified detection of dynamic hyperinflation. Chest. 2007 Mar;131(3):690-5. Gelb AF, Hogg JC, Müller NL, Schein MJ, Kuei J, Tashkin DP, Epstein JD, Kollin J, Green RH, Zamel N, Elliott WM, Hadjiaghai L. Contribution of emphysema and small airways in COPD. Chest. 1996 Feb;109(2):353-9.
Starting date: August 2004
Last updated: August 13, 2008
|